clinical trial · NCT06496217
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
Renal ImpairmentMBX 2109MBX 2109MBX 2109MBX 2109
brief summary
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
started
Jun 13, 2024
primary completion
Sep 4, 2025
completion
Sep 4, 2025
last updated
Oct 28, 2025
detailed description
A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
official title
A Phase 1, Open-Label, Parallel-Group, Single Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol